Related Experiment Video

Updated: Dec 12, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.5K

D-dimer and the incidence of heart failure and mortality after acute myocardial infarction

Xiaoyuan Zhang1,2, Shanjie Wang1,2, Jinxin Liu1,2

  • 1Department of Cardiology, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

Heart (British Cardiac Society)
|August 14, 2020
PubMed

Insights

Elevated D-dimer levels after acute myocardial infarction (AMI) correlate with increased risk of heart failure (HF) post-hospitalization and all-cause mortality. Baseline D-dimer is a significant prognostic marker in AMI patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Thrombosis

Background:

  • D-dimer indicates thrombogenesis and hypercoagulable states post-plaque rupture.
  • Limited research exists on baseline D-dimer and heart failure (HF) incidence or mortality in acute myocardial infarction (AMI) populations.

Purpose of the Study:

  • To investigate the association between baseline D-dimer levels and the incidence of HF and all-cause mortality in patients with AMI.

Main Methods:

  • Prospective cohort study of 4504 consecutive AMI patients with complete data.
  • Analysis of plasma D-dimer levels on admission concerning HF incidence and all-cause mortality.

Main Results:

  • Over 1-year follow-up, 16.7% developed HF post-hospitalization and 7.1% died.
  • Higher D-dimer quartiles (Q3, Q4) were associated with increased risk of post-hospitalization HF (HR 1.51-1.49).
  • Highest D-dimer quartile (Q4) showed a >2-fold increased risk of all-cause mortality (HR 2.34). No association with in-hospital HF.

Conclusions:

  • Baseline D-dimer levels are associated with the incidence of heart failure after hospitalization and all-cause mortality in patients with acute myocardial infarction.
  • D-dimer serves as a prognostic indicator for adverse outcomes in AMI patients.
Abstract

Keywords:
acute myocardial infarctionheart failure

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.7K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

448

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
122
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
288
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
653
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
178
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
295
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
407